Flputnam Investment Management Co. Makes New $3.11 Million Investment in AirSculpt Technologies, Inc. $AIRS

Flputnam Investment Management Co. acquired a new stake in shares of AirSculpt Technologies, Inc. (NASDAQ:AIRS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 691,989 shares of the company’s stock, valued at approximately $3,114,000.

A number of other institutional investors and hedge funds have also made changes to their positions in AIRS. Larson Financial Group LLC increased its holdings in shares of AirSculpt Technologies by 20.4% during the 3rd quarter. Larson Financial Group LLC now owns 15,137 shares of the company’s stock worth $121,000 after buying an additional 2,561 shares during the last quarter. Wexford Capital LP grew its position in AirSculpt Technologies by 2.6% during the third quarter. Wexford Capital LP now owns 102,614 shares of the company’s stock valued at $823,000 after acquiring an additional 2,614 shares during the period. Rhumbline Advisers grew its position in AirSculpt Technologies by 16.1% during the third quarter. Rhumbline Advisers now owns 20,782 shares of the company’s stock valued at $167,000 after acquiring an additional 2,876 shares during the period. Creative Planning grew its position in AirSculpt Technologies by 32.2% during the second quarter. Creative Planning now owns 13,225 shares of the company’s stock valued at $64,000 after acquiring an additional 3,224 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in AirSculpt Technologies by 239.5% during the third quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock worth $48,000 after acquiring an additional 4,199 shares during the last quarter. 91.54% of the stock is currently owned by institutional investors and hedge funds.

AirSculpt Technologies Price Performance

AIRS stock opened at $3.43 on Monday. The firm has a market cap of $247.30 million, a P/E ratio of -19.05 and a beta of 2.33. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.79 and a current ratio of 0.79. AirSculpt Technologies, Inc. has a 1 year low of $1.51 and a 1 year high of $12.00. The stock has a 50-day simple moving average of $4.53 and a 200-day simple moving average of $3.57.

AirSculpt Technologies (NASDAQ:AIRS) last released its quarterly earnings results on Monday, August 10th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $42.90 million for the quarter, compared to analyst estimates of $44.14 million. AirSculpt Technologies had a negative return on equity of 5.83% and a negative net margin of 7.79%.

Wall Street Analysts Forecast Growth

AIRS has been the topic of a number of research reports. Weiss Ratings upgraded AirSculpt Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Leerink Partners set a $4.50 target price on AirSculpt Technologies in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of AirSculpt Technologies from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, AirSculpt Technologies presently has an average rating of “Reduce” and an average price target of $4.50.

AirSculpt Technologies Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.